These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

168 related articles for article (PubMed ID: 23406084)

  • 1. Recommendations on the potency labelling of factor VIII and factor IX concentrates.
    Hubbard AR; Dodt J; Lee T; Mertens K; Seitz R; Srivastava A; Weinstein M;
    J Thromb Haemost; 2013 May; 11(5):988-9. PubMed ID: 23406084
    [No Abstract]   [Full Text] [Related]  

  • 2. The design and analysis of half-life and recovery studies for factor VIII and factor IX. Factor VIII/Factor IX Scientific and Standardization Committee of the International Society for Thrombosis and Haemostasis.
    Morfini M; Lee M; Messori A
    Thromb Haemost; 1991 Sep; 66(3):384-6. PubMed ID: 1746011
    [No Abstract]   [Full Text] [Related]  

  • 3. New challenges and best practices for the laboratory monitoring of factor VIII and factor IX replacement.
    Van den Bossche D; Peerlinck K; Jacquemin M
    Int J Lab Hematol; 2018 May; 40 Suppl 1():21-29. PubMed ID: 29741261
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Pharmacokinetics of factor VIII and factor IX.
    Morfini M
    Haemophilia; 2003 May; 9 Suppl 1():94-9; discussion 100. PubMed ID: 12709044
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Comparative pharmacokinetic studies in haemophilia.
    Morfini M
    Haemophilia; 2002 Mar; 8 Suppl 2():30-3. PubMed ID: 11966850
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Role of enhanced half-life factor VIII and IX in the treatment of haemophilia.
    Mahdi AJ; Obaji SG; Collins PW
    Br J Haematol; 2015 Jun; 169(6):768-76. PubMed ID: 25754016
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Potency determination of factor VIII and factor IX for new product labelling and postinfusion testing: challenges for caregivers and regulators.
    Dodt J; Hubbard AR; Wicks SJ; Gray E; Neugebauer B; Charton E; Silvester G
    Haemophilia; 2015 Jul; 21(4):543-9. PubMed ID: 25623631
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The price of enhanced half-life factor IX.
    Messori A; Trippoli S
    Blood Transfus; 2017 Jul; 15(4):378. PubMed ID: 27893358
    [No Abstract]   [Full Text] [Related]  

  • 9. Factor VIII and IX assays for post-infusion monitoring in hemophilia patients: Guidelines from the French BIMHO group (GFHT).
    Jeanpierre E; Pouplard C; Lasne D; Le Cam Duchez V; Eschwege V; Flaujac C; Galinat H; Harzallah I; Proulle V; Smahi M; Sobas F; Stepina N; Toulon P; Voisin S; Ternisien C; Nougier C;
    Eur J Haematol; 2020 Aug; 105(2):103-115. PubMed ID: 32277501
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Laboratory assay measurement of modified clotting factor concentrates: a review of the literature and recommendations for practice.
    Young GA; Perry DJ;
    J Thromb Haemost; 2019 Apr; 17(4):567-573. PubMed ID: 30667575
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Stretching time.
    Savage N
    Sci Am; 2015 Jan; 312(1):S8-10. PubMed ID: 25597117
    [No Abstract]   [Full Text] [Related]  

  • 12. Switching to extended half-life products in Canada - preliminary data.
    Keepanasseril A; Stoffman J; Bouskill V; Carcao M; Iorio A; Jackson S;
    Haemophilia; 2017 Jul; 23(4):e365-e367. PubMed ID: 28548284
    [No Abstract]   [Full Text] [Related]  

  • 13. Pharmacokinetic and safety considerations when switching from standard to extended half-life clotting factor concentrates in hemophilia.
    Morfini M; Farrugia A
    Expert Rev Hematol; 2019 Oct; 12(10):883-892. PubMed ID: 31314609
    [No Abstract]   [Full Text] [Related]  

  • 14. Importance of pharmacokinetics in the management of hemophilia.
    Barnes C
    Pediatr Blood Cancer; 2013; 60 Suppl 1():S27-9. PubMed ID: 23109436
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Potency labeling of novel factor VIII and factor IX concentrates: past experience and current strategy.
    Hubbard AR
    Semin Thromb Hemost; 2015 Nov; 41(8):849-54. PubMed ID: 25703515
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Implications of coagulation factor VIII and IX pharmacokinetics in the prophylactic treatment of haemophilia.
    Collins PW; Fischer K; Morfini M; Blanchette VS; Björkman S;
    Haemophilia; 2011 Jan; 17(1):2-10. PubMed ID: 20731726
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The use of enhanced half-life coagulation factor concentrates in routine clinical practice: guidance from UKHCDO.
    Collins P; Chalmers E; Chowdary P; Keeling D; Mathias M; O'Donnell J; Pasi KJ; Rangarajan S; Thomas A
    Haemophilia; 2016 Jul; 22(4):487-98. PubMed ID: 27311929
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Estimating and interpreting the pharmacokinetic profiles of individual patients with hemophilia A or B using a population pharmacokinetic approach: communication from the SSC of the ISTH.
    Iorio A; Blanchette V; Blatny J; Collins P; Fischer K; Neufeld E
    J Thromb Haemost; 2017 Dec; 15(12):2461-2465. PubMed ID: 29119666
    [No Abstract]   [Full Text] [Related]  

  • 19. Why prescribe highly purified factor VIII and IX concentrates?
    Berntorp E
    Vox Sang; 1996; 70(2):61-8. PubMed ID: 8801765
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Initiation of Pediatric Clinical Trials for Coagulation Factors: Application of Pharmacokinetics and Allometry to First-in-Pediatric Dose Selection.
    Mahmood I
    J Clin Pharmacol; 2019 Jun; 59(6):829-834. PubMed ID: 30624769
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.